Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
RUT
Market Cap
507.20M
Enterprise Value
224.30M
Income
-178.24M
Sales
15.00M
Book/sh
7.08
Cash/sh
7.44
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
44
IPO
Jan 10, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
33.81
P/B
1.84
P/C
1.75
P/FCF
-
EV/EBITDA
-
EV/Sales
14.95
Quick Ratio
12.57
Current Ratio
12.57
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-7.13
EPS next Y
-3.62
EPS next Q
-0.95
EPS this Y
74.03%
EPS next Y
-8.92%
EPS next 5Y
31.39%
EPS past 3/5Y
45.01% 33.26%
Sales past 3/5Y
424.86% 1.31%
EPS Y/Y TTM
67.56%
Sales Y/Y TTM
-100.00%
EPS Q/Q
35.07%
Sales Q/Q
-
Insider Own
16.78%
Insider Trans
13.35%
Inst Own
91.75%
Inst Trans
15.65%
ROA
-81.43%
ROE
-91.19%
ROIC
-64.58%
Gross Margin
98.33%
Oper. Margin
-1216.61%
Profit Margin
-1188.29%
SMA20
-3.36%
SMA50
-10.11%
SMA200
-18.44%
Trades
Shs Outstand
38.18M
Shs Float
32.37M
52W High
27.41 -52.43%
52W Low
8.72 49.54%
Volatility
9.56% 7.94%
ATR (14)
1.12
RSI (14)
43.88
Beta
1.37
Rel Volume
0.00
Avg Volume
350.54K
Volume
0
Perf Week
-6.32%
Perf Month
5.50%
Perf Quarter
-24.71%
Perf Half Y
-29.44%
Perf YTD
9.95%
Perf Year
-0.23%
Perf 3Y
-91.01%
Perf 5Y
-93.28%
Perf 10Y
-98.00%
Prev Close
13.04
Price
13.04
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$32.33
Implied Upside
+147.9%
Analysts12incl. previous ratings
Rating Distribution9 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 06, 2026Upgrade
HH.C. Wainwright
Neutral → Buy$36+176.1%
Jun 01, 2026Downgrade
HH.C. Wainwright
Buy → Neutral
Jan 28, 2026Initiated
PPiper Sandler
Overweight$35+168.4%
Jan 21, 2026Initiated
GGuggenheim
Buy$35+168.4%
Aug 25, 2025Initiated
JEF logoJJefferies
Buy$26+99.4%
Aug 11, 2025Initiated
HH.C. Wainwright
Buy$25+91.7%
Jul 14, 2025Initiated
WWedbush
Outperform$27+107.1%
Jun 25, 2025Initiated
SF logoSStifel
Buy$28+114.7%
Mar 21, 2025Initiated
CCantor Fitzgerald
Overweight
Jul 26, 2024Downgrade
TD logoTTD Cowen
Buy → Hold
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lynch RyanSee RemarksSep 16 '26Sale17.902404,29613,631Sep 18 04:03 PM
Pinkas JanChief Scientific OfficerSep 16 '26Sale17.9065811,77821,581Sep 18 04:03 PM
Im Ellie EunkyungChief Medical OfficerSep 16 '26Sale17.9062311,15221,446Sep 18 04:02 PM
Scalzo Richard WilliamChief Financial OfficerSep 16 '26Sale17.9056810,16719,730Sep 18 04:02 PM
Bispham Barbara HarlinSee RemarksSep 16 '26Sale17.9062011,09818,710Sep 18 04:02 PM
Brumm Joshua TChief Executive OfficerSep 18 '26Sale16.717,837130,956271,765Sep 18 04:02 PM
Brumm Joshua TChief Executive OfficerSep 16 '26Sale17.901,61028,819279,602Sep 18 04:02 PM
McNeill JonathanPresident and COOSep 18 '26Sale16.713,83964,150134,588Sep 18 04:01 PM
McNeill JonathanPresident and COOSep 16 '26Sale17.9073113,085138,427Sep 18 04:01 PM
Joshua T BrummOfficerSep 18 '26Proposed Sale17.189,013154,843Sep 17 04:33 PM
Jonathan McNeillOfficerSep 18 '26Proposed Sale17.184,41575,850Sep 17 04:32 PM
Jonathan McNeillOfficerSep 16 '26Proposed Sale18.8080415,115Sep 16 03:09 PM
Joshua T BrummOfficerSep 16 '26Proposed Sale18.801,77133,295Sep 16 03:09 PM
Fairmount Funds Management LLCDirectorJul 16 '26Buy14.50853,45012,375,0253,601,316Jul 20 05:30 PM
Lynch RyanSee RemarksJun 22 '26Sale17.994658,36513,871Jun 23 04:04 PM
Pinkas JanChief Scientific OfficerJun 22 '26Sale17.991,28823,17122,239Jun 23 04:04 PM
Scalzo Richard WilliamChief Financial OfficerJun 22 '26Sale17.991,11220,00520,298Jun 23 04:03 PM
Bispham Barbara HarlinSee RemarksJun 22 '26Sale17.991,21821,91219,330Jun 23 04:03 PM
Im Ellie EunkyungChief Medical OfficerJun 22 '26Sale17.991,21921,93022,069Jun 23 04:02 PM
McNeill JonathanPresident and COOJun 22 '26Sale17.9920,549369,677139,158Jun 23 04:02 PM
Brumm Joshua TChief Executive OfficerJun 22 '26Sale17.9942,305761,067281,212Jun 23 04:01 PM
Fairmount Funds Management LLCDirectorDec 04 '25Buy13.411,360,00018,237,6002,747,866Dec 08 04:30 PM
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
CEO & DirectorMr. Joshua T. Brumm
President & COODr. Jonathan McNeill M.D.
Chief Medical OfficerDr. Ellie Im M.D.
Chief Financial OfficerMr. Richard William Scalzo M.B.A.
Senior VP of FinanceMr. Ryan Lynch